40% of Sanofi's market is in a hurry? Sichuan pharmaceutical companies have entered the market with more than 1 billion anti-epileptic injections

Pharmaceutical Network February 2nd, January 30th, CDE official website shows that Chengdu Yuandong Biopharmaceutical sodium valproate injection with a thick solution to mimic the 3 categories of production was accepted.
recently, Chengdu Lear Pharmaceuticals sodium valium acetate injection with a thick solution to imitate the 3 categories of applications submitted for listing in the review and approval (in the drug review center).
meters of intranet data show that in 2018, China's public medical institutions terminal sodium valproate injection sales exceeded the 1 billion mark, in 2019 to a new high, the first half of 2020 slightly decline.
recent years, China's public medical institutions terminal sodium valproate injection sales source: China's public medical institutions terminal competition pattern of sodium valproate belongs to broad-spectrum anti-epileptic drugs. In recent years, sales of sodium valproate injections at the end of urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) have steadily increased, reaching new highs in 2019 and a slight decline in the first half of 2020 after breaking the 1 billion mark in 2018, according to
meters of intranet data.
Currently, sodium valproate injections are only approved for sale with sodium valproate for injection, and the product is a TOP1 product for anti-epileptic drugs, manufactured by Sanofi, Shenyang Xinma Pharmaceuticals and Sichuan Corede Pharmaceuticals.
note that Sanofi's market share has been declining over the past two years, from 46.42 per cent in 2018 to 40.64 per cent in the first half of 2020.
source: MED2.0 China Drug Review Database Prior to this, sodium valium val has been injected with a strong solution in Chengdu Lil Pharmaceuticals to copy 3 categories of applications submitted for listing in the review and approval (in the drug review center).
Sodium valproate injection has Fu'an Pharmaceutical Group Qingyutang Pharmaceuticals, Hebei Ren Heyikang Pharmaceuticals and other 4 are copied 3 categories of submitted for listing applications in the review and approval (in the drug review center).
source: CDE official website, Mienet database